Viatris Inc.’s Stock Price Tumbles to $12.29, Plunging by a Sharp 7.11% – A Deep Dive into VTRS Performance

Viatris Inc. (VTRS)

12.29 USD -0.94 (-7.11%) Volume: 26.66M

Viatris Inc.’s stock price is currently valued at 12.29 USD, witnessing a decline of 7.11% this trading session with a trading volume of 26.66M, despite a year-to-date percentage change of +13.48%, indicating a volatile yet promising investment opportunity.

Latest developments on Viatris Inc.

Despite facing earnings hurdles and weak Q4 results, Viatris (VTRS) remains a key player in the pharmaceutical industry. The company recently missed its Q4 estimates, leading to a 7.11% drop in stock prices. However, a groundbreaking R&D collaboration with Idorsia, backed by a $350M upfront investment, has created a positive buzz. This partnership will focus on the development of innovative cardio and autoimmune therapies. Moreover, Viatris projects a revenue surge in 2024, driven by high demand for its key medications, Yupelri and Breyna.

Viatris Inc. on Smartkarma

According to recent analyst coverage on Smartkarma, Viatris, a global pharmaceutical company, has failed to meet Wall Street’s revenue and earnings expectations. The company’s third quarter results showed a 1% year-over-year growth in total revenues, with an adjusted EBITDA of $1.36 billion and free cash flow of $738 million. However, the company’s performance was deemed a major disappointment by Baptista Research, whose report on Smartkarma analyzed Viatris‘ historical financial statements.

Despite the disappointing results, Baptista Research also published a report highlighting the potential of Viatris‘ popular brands like Lipitor and Lyrica. In the previous quarter, the company exceeded analyst expectations with total revenues of $3.9 billion, a 2% year-over-year growth on an operational adjusted basis, and an adjusted EBITDA of $1.3 billion. The report also mentioned the company’s efforts to improve its bridge program for Tyrvaya, which is expected to increase the value per prescription and boost the company’s performance.

A look at Viatris Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Viatris Inc., a global pharmaceutical company, is poised for long-term success according to the Smartkarma Smart Scores. The company has received high scores in multiple categories, including value, dividend, and growth, indicating a strong overall outlook. Viatris is committed to producing medicines for a wide range of diseases, both noncommunicable and infectious, making it a valuable asset for patients around the world.

With a score of 5 in value, Viatris is considered a financially sound company, offering attractive investment opportunities. Its high dividend score of 5 is a promising sign for investors looking for steady returns. Additionally, the company’s focus on growth, with a score of 5, demonstrates its potential for future success. However, Viatris received a lower score of 2 in resilience, indicating potential challenges in weathering unexpected events. Overall, with a momentum score of 4, Viatris is well-positioned for long-term growth and success in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

Before it’s here, it’s on Smartkarma